Biocon Biologics serves patients in U.S., Canada, EU, Japan, Latin America, Africa, Middle East and Turkey, and the Asia-Pacific through its wide biosimilar portfolio. We can effectively manage the risks entailed in taking advanced therapies from ‘bench to bedside’, even in the most stringently regulated markets.
Biocon Biologics is the first biosimilar insulins company to promote and support IDF’s Core Mission initiative and activities under its ‘Mission 10 cents’ program which was launched in 2019 to unlock universal access to high quality human insulin (rh-Insulin), by offering it at less than 10 US cents / day for Governments in Low and Middle-Income Countries (LMICs). The announcement was made at a UNAIDS Health Innovation Exchange event held on the side-lines of the 74th session of the UN General Assembly in New York. Biocon Biologics has recently rolled out this program in LMICs like Philippines & Tanzania. This partnership with IDF further strengthens the shared vision of providing universal access to insulins globally to tackle a broad range of diabetes issues, create awareness, educate and advocate effective management of diabetes.
In the oncology space, Biocon Biologics has signed an agreement with the Clinton Health Access Initiative (CHAI) to expand access to lifesaving cancer biosimilars in over 30 countries in Africa and Asia as a part of the Cancer Access Partnership (CAP). The partnership is a significant step in delivering advanced cancer therapies to patients who need them the most and ensuring equitable access to high-quality biosimilars in low- and middle-income countries (LMICs).